Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
<p>Abstract</p> <p>Background</p> <p>Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-09-01
|
| Series: | BMC Infectious Diseases |
| Online Access: | http://www.biomedcentral.com/1471-2334/10/267 |
| _version_ | 1828242619234254848 |
|---|---|
| author | Diaz Asuncion Diez Mercedes Bleda Maria Aldamiz Mikel Camafort Miguel Camino Xabier Cepeda Concepcion Costa Asuncion Ferrero Oscar Geijo Paloma Iribarren Jose Moreno Santiago Moreno Maria Labarga Pablo Pinilla Javier Portu Joseba Pulido Federico Rosa Carmen Santamaría Juan Telenti Mauricio Trapiella Luis Trastoy Monica Viciana Pompeyo |
| author_facet | Diaz Asuncion Diez Mercedes Bleda Maria Aldamiz Mikel Camafort Miguel Camino Xabier Cepeda Concepcion Costa Asuncion Ferrero Oscar Geijo Paloma Iribarren Jose Moreno Santiago Moreno Maria Labarga Pablo Pinilla Javier Portu Joseba Pulido Federico Rosa Carmen Santamaría Juan Telenti Mauricio Trapiella Luis Trastoy Monica Viciana Pompeyo |
| author_sort | Diaz Asuncion |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion.</p> <p>Methods</p> <p>Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI).</p> <p>Results</p> <p>A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9).</p> <p>Conclusions</p> <p>A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.</p> |
| first_indexed | 2024-04-12T22:17:57Z |
| format | Article |
| id | doaj.art-dc2fc884cb54434fa011ba12677721e9 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-12T22:17:57Z |
| publishDate | 2010-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-dc2fc884cb54434fa011ba12677721e92022-12-22T03:14:28ZengBMCBMC Infectious Diseases1471-23342010-09-0110126710.1186/1471-2334-10-267Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in SpainDiaz AsuncionDiez MercedesBleda MariaAldamiz MikelCamafort MiguelCamino XabierCepeda ConcepcionCosta AsuncionFerrero OscarGeijo PalomaIribarren JoseMoreno SantiagoMoreno MariaLabarga PabloPinilla JavierPortu JosebaPulido FedericoRosa CarmenSantamaría JuanTelenti MauricioTrapiella LuisTrastoy MonicaViciana Pompeyo<p>Abstract</p> <p>Background</p> <p>Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion.</p> <p>Methods</p> <p>Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI).</p> <p>Results</p> <p>A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9).</p> <p>Conclusions</p> <p>A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.</p>http://www.biomedcentral.com/1471-2334/10/267 |
| spellingShingle | Diaz Asuncion Diez Mercedes Bleda Maria Aldamiz Mikel Camafort Miguel Camino Xabier Cepeda Concepcion Costa Asuncion Ferrero Oscar Geijo Paloma Iribarren Jose Moreno Santiago Moreno Maria Labarga Pablo Pinilla Javier Portu Joseba Pulido Federico Rosa Carmen Santamaría Juan Telenti Mauricio Trapiella Luis Trastoy Monica Viciana Pompeyo Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain BMC Infectious Diseases |
| title | Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain |
| title_full | Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain |
| title_fullStr | Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain |
| title_full_unstemmed | Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain |
| title_short | Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain |
| title_sort | eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of hiv infected people in spain |
| url | http://www.biomedcentral.com/1471-2334/10/267 |
| work_keys_str_mv | AT diazasuncion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT diezmercedes eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT bledamaria eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT aldamizmikel eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT camafortmiguel eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT caminoxabier eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT cepedaconcepcion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT costaasuncion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT ferrerooscar eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT geijopaloma eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT iribarrenjose eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT morenosantiago eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT morenomaria eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT labargapablo eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT pinillajavier eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT portujoseba eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT pulidofederico eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT rosacarmen eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT santamariajuan eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT telentimauricio eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT trapiellaluis eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT trastoymonica eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain AT vicianapompeyo eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain |